Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2017 Summary C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2017, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis. Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects - The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview 6 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development 20 AFFiRiS AG 20 ChemoCentryx Inc 20 Dompe Farmaceutici SpA 21 Novo Nordisk A/S 21 Prommune Inc 22 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles 23 ALS-205 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 avacopan - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 DF-2593A - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Drug to Antagonize C5aR for Periodontitis - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 EP-67 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Monoclonal Antibody to Antagonize C5aR for Rheumatoid Arthritis and Lewis Lung Cancer - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Vaccine to Target C5a for Alzheimer's Disease - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products 36 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products 37 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones 38 Featured News & Press Releases 38 Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan 38 May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 38 Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 39 Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan 39 Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan') 41 Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 42 Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 42 Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 44 Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 44 Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 46 May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 47 Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 49 Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 49 Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 50 Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 16 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by AFFiRiS AG, H2 2017 20 Pipeline by ChemoCentryx Inc, H2 2017 20 Pipeline by Dompe Farmaceutici SpA, H2 2017 21 Pipeline by Novo Nordisk A/S, H2 2017 21 Pipeline by Prommune Inc, H2 2017 22 Dormant Projects, H2 2017 36 Discontinued Products, H2 2017 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
